iVexSol
Lexington
About iVexSol
IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs. The platform's low-cost, highly scalable Intelligent Vector Solutions are intended to alleviate the vector supply bottleneck and increase access to life-saving treatments for patients. Intelligent Vector Solutions from iVexSol are revolutionizing the production of LVVs, which are gene delivery vehicles that are a critical raw material in the manufacture of life-changing cell and gene therapies (CGTs). The technology platform employs banks of vector-producing cells to produce LVV in significantly greater quantities than current approaches while allowing for the rapid scale-out required for global demand, all within a smaller manufacturing footprint. These advancements allow for shorter clinical development timelines, lower costs, and, ultimately, greater global access for patients who are waiting for these transformative medicines.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $39.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2023)
- Website: ivexsol.com
Industries & Categories
Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/ivexsol-50565 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.